Illumina, Inc. (ILMN) Stock: What Does the Chart Say Monday?

Illumina, Inc. (ILMN) stock has fallen 8.41% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Illumina, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ILMN!

See Full ILMN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ILMN Stock Today?

Illumina, Inc. (ILMN) stock is trading at $348.83 as of 1:04 PM on Monday, Jan 10, a drop of -$21.53, or -5.81% from the previous closing price of $370.36. The stock has traded between $346.15 and $363.17 so far today. Volume today is less active than usual. So far 559,170 shares have traded compared to average volume of 1,008,085 shares. To screen for more stocks like Illumina, Inc. click here.

More About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing. Click Here to get the full Stock Report for Illumina, Inc. stock.